Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01310972

Enrollment

Registered

2011-03-09

Start date

2007-09-30

Completion date

2007-09-30

Last updated

2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

Adjuvant Colon Cancer

Brief summary

Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Detailed description

It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.

Interventions

OTHERRegistry

Registry

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

14 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients with Adjuvant Colon Cancer

Exclusion criteria

* Patients with diagnosis other than Colon Cancer.

Design outcomes

Primary

Measure	Time frame
OS, PFS, DFS	For the duration of the experiment

Countries

Saudi Arabia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026